Showing posts with label ovarian. Show all posts
Showing posts with label ovarian. Show all posts

Friday, 30 June 2023

Novel Approach for Poor Ovarian Reserve with Autologous Platelet Rich Plasma (PRP) Therapy| Chapter 11 | New Advances in Medicine and Medical Science Vol. 7

 The present study was attended to observe the influence of platelet rich plasma infusion through calculation of AMH and AFC values and gestation outcomes. Though ovarian becoming older is a normal process but the term Poor ovarian reserve (POR) implies when the condition and quantity of the follicular pool decreases in mothers with generative age groups. Sometimes the condition becomes an obstacle for gestation and compromising pregnancy.  It may be seen in state-of-the-art years of generative life or without some reason or may happen in young women accompanying different etiological factors. Women accompanying poor ovarian reserve concede possibility be evaluated correctly and individualising their therapeutic strategies for optimizing the fame rate. Majority of women accompanying POR need to undergo artificial fertilization to achieve gestation. Sometimes ovum gift and embryo gift are not acceptable to some couples for disturb-social reason or conscientious reason. To improve the position many treatment approaches have been intentional. Among them individual of the novel approaches is Autologous platelet rich plasma healing.This prospective observational study was exhausted the department of generative endocrinology and infertility from July 2019 to June 2022. A total of 60 inmates with weak ovarian reserve were recruited maintaining addition and exclusion tests.At first cycle, distinguished to baseline counts, mean±SD AMH had increased by 0.04±0.15 ng/dl, and mean±SD AFC had raised by 1.34±1.89 in number. During second cycle post-PRP, the mean distinctness of AMH and AFC was 0.18±0.21 ng/dl and 2.17±1.71 in a positive tone. By final follow-up, gestation rate was 20% among cases. Ovarian PRP infusion had a  gestation success rate of 23.33%, which was comparable to other prior studies with identical short follow-up history. 18,21-23 PRP had existed proven expected an effective means for ovarian rejuvenation in terms of AMH and AFC in the study.Following PRP infusion, the study proverb a considerable bettering in AMH and AFC values. Both results gradually enhanced; an increase in AMH values was visualized up to the second post-PRP period, while an increase in AFC was shown until the third cycle post-PRP. Twelve (12) of the 60 subjects (20%) were pregnant. PRP ovarian situation resulted in revised oocyte and embryo quality in nearly three-fourths of patients and use of this medicine would therefore likely increase the success rate of IVF eras in poor responders.

Author(s) Details:

Jesmine Banu,
Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, Bangladesh.

Mostafa Tarique,
Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, Bangladesh.

Nishat Jahan,
Department of Gynecology, Nabinagar Upazila Health Complex, Brahmanbaria, Bangladesh.

Nastaran Lasker,
Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, Bangladesh.

Nighat Sultana,
Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, Bangladesh.

Chowdhury Faisal Alamgir,
Department of Urology, New Cross Hospital, The Royal Wolverhampton NHS Trust, United Kingdom.

Maliha Darmini,
Department of Gynecology, Mymensingh Medical College and Hospital, Mymensingh, Bangladesh.

S. M. Munira,
Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, Bangladesh.

Please see the link here: https://stm.bookpi.org/NAMMS-V7/article/view/11041

Thursday, 23 February 2023

Detection of Ovarian Cancer: Combined Use of CA 125 and Inhibin as Tumor Marker | Chapter 1 | Research Highlights in Disease and Health Research Vol. 2

 The current study compares the efficiency of a combined test utilizing CA 125 and Inhibin for early detection of ovarian tumor to CA125 or Inhibin alone. Fifty daughters attending Gynae OPD accompanying clinical trace of ovarian malignancy were contained in the study. Prior to surgery, all of these mothers had their CA 125 and Inhibin levels measured. The verdicts showed that Out of 50 sufferers recruited, 30 (60%) were erect to have carcinoma ovary and 20 (40%) were establish to have benign ailments. Out of 30 cases of carcinoma ovary, CA125 was elevated in 81% of cases and Inhibin was raised in 78% of cases. CA 125 was erect to have a sensitivity of 90% and precision of 60% for detecting carcinoma ovary, accompanying a statistically significant certain predictive advantage of 77% and negative predictive worth of 80%.  The sensitivity and particularity of serum Inhibin for the alike were 86.6% and 20%, respectively. The definite and negative predictive principles were 61.9% and 50%, respectively, and were not statistically meaningful. The combined CA125 and Inhibin sense and specificity were 100% and 30%, individually. The positive and negative predicting principles were 68.1% and 100%, respectively, and were statically main. In comparison to CA125 or Inhibin used unique, the combination of CA125 and Inhibin has greater sensitivity and particularity in detecting ovarian cancer.

Author(s) Details:

Avinash P. Dubbewar,
Department of Obstetrics and Gynecology, AFMS, New Delhi, India.

Ravishekar N. Hiremath,
Department of Community Medicine, AFMS, New Delhi, India.

Kasi Viswanath,
Department of Community Medicine, AFMS, New Delhi, India.

Sandhya Ghodke,
Department of Anaesthesiology, Rainbow Children Hospital, Bangalore, India.

B. Pathak,
Department of Obstetrics and Gynecology, AFMS, New Delhi, India.

Manas Biswas,
Department of Obstetrics and Gynecology, AFMS, New Delhi, India.

Gunjan Malhotra,
Department of Obstetrics and Gynecology, AFMS, New Delhi, India.


Prathyusha Gouru,
Department of Obstetrics and Gynecology, AFMS, New Delhi, India

Preeti Yadav,
Department of Obstetrics and Gynecology, AFMS, New Delhi, India.

Please see the link here: https://stm.bookpi.org/RHDHR-V2/article/view/9610